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Rob G. Ackerstaff, MD, PhD,d on behalf of the Antonius Carotid Endarterectomy, Angioplasty, and
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Objectives: This study compared transcranial Doppler (TCD) imaging and outcomes of carotid angioplasty and stenting
(CAS) in stenosis after carotid endarterectomy (CEA) vs primary atherosclerotic stenoses.
Methods: A prospectively accumulated database of 812 CAS procedures was analyzed retrospectively. Two groups were
created. Group 1 had 72 restenoses at a mean of 71 months (range, 5-245 months) after initial CEA. Group 2 had 740
primary stenoses. Clinical end points were cerebral ischemic events and death. TCD end points were numbers of isolated
microemboli and microembolic showers during five procedural phases.
Results: Groups 1 and 2 were evenly matched for demographic data: median age, 70 vs 71 years; 44 (61%) vs 525 men
(71%); 14 (19%) vs 147 symptomatic (20%). Seven (0.9%) deaths and 10 major (1.2%) and 21 minor (2.6%) strokes
occurred in group 2 (P  .049). Mean (standard deviation) numbers of isolated microemboli for groups 1 vs 2 were
wiring, 37.0 (31.1) vs 50.4 (52.6); predilation, 14.8 (18.7) vs 21.7 (21.8); stent placement, 58.6 (31.1) vs 64.7 (38.8);
postdilation, 20.4 (16.5) vs 27.2 (34.9), cerebral protection device (CPD) use, 44.2 (30.2) vs 37.5 (36.8); total, 134.8
(68.7) vs 175.3 (113.8). Microembolic showers: wiring, 1.7 (4.5) vs 2.2 (6.4); predilation, 2.1 (4.1) vs 3.3 (5.8); stent
placement, 21.5 (22.0) vs 26.9 (25.1); postdilation, 5.3 (15.7) vs 5.0 (8.1); CPD use, 5.8 (6.9) vs 6.2 (8.9); total, 30.4
(36.0) vs 39.6 (35.0). TCD data for CPD use vs without for isolated emboli: wiring, 53.2 (45.1) vs 44.3 (51.7);
predilation, 24.7 (20.2) vs 18.2 (22.5); stent placement, 77.5 (34.8) vs 53.5 (37.3); postdilation, 33.6 (36.6) vs 20.7
(21.8); CPD use, 38.3 (36.6) vs 0; total, 222.5 (113.8) vs 132.3 (89.1). Showers: wiring, 2.4 (6.6) vs 1.9 (5.8);
predilation, 4.2 (6.4) vs 2.4 (5.0); stent placement, 38.9 (25.8) vs 16.2 (18.7); post-dilation, 7.0 (11.2) vs 3.4 (6.4); CPD
use, 6.3 (8.9) vs 0; total, 58.4 (37.7) vs 23.3 (23.1). P  .01 for showers during wiring and P < .001 for all other
variables. After correction for the difference in CPD use between groups 1 and 2 (17 out of 72 [24%] vs 369 out of 740
[50%]), no statistically significant differences remained in numbers of isolated emboli and embolic showers in the
procedural phases or for the entire procedure. No statistically significant differences were found when TCD-detected
microembolic load for early (<3 years between CEA and CAS) and late (>5 years) restenoses were compared.
Conclusions: CAS for restenosis after CEA has a complication rate lower than primary CAS. The time interval between
CEA and CAS did not influence micro embolic load. (J Vasc Surg 2009;50:755-61.)Because of the results of several large randomized trials,
carotid endarterectomy (CEA) is currently the accepted
standard treatment for patients with severe symptomatic
and asymptomatic carotid artery stenosis.1-4 Carotid angio-
plasty and stenting (CAS) has been evaluated as a potential
alternative to CEA.5 Compared with the surgical approach,
the endovascular procedure is associated with a significant
cerebral embolic burden, as shown by transcranial Doppler
(TCD) imaging of the ipsilateral middle cerebral artery6,7
and magnetic resonance imaging (MRI) of the brain.8,9
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doi:10.1016/j.jvs.2009.04.060Postoperative restenosis after CEA, defined as a 50%
diameter reduction, has been reported with incidences of
6% to 36%,10 partly depending on follow-up length. On
account of scar tissue in the cervical region and the loss of
tissue planes, redo operations are generally considered to be
technically more challenging, andmost reports cite a higher
complication rate.11 Because CAS is not hampered by
previous neck dissection, it has been considered as an
alternative to redo surgery in these patients, and encourag-
ing results have been published within the last decade.12-16
The main culprit in early restenosis after CEA is hy-
pothesized to be myointimal hyperplasia (MIH), whereas
late restenosis is generally considered to result from pro-
gression of the underlying atherosclerotic disease.17 Be-
cause MIH is supposed to be more stable and less embolo-
genic,18 the procedural risk of emboli might be lower in
CAS after prior ipsilateral CEA compared with primary
CAS, especially in early restenoses.
We have previously reported our experience with TCD
monitoring and its usefulness with regard to emboli detec-
tion and the prediction of early cerebral outcome in
755
4 mo
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load and clinical outcome in patients who underwent stent
placement for restenosis after prior ipsilateral CEA was
compared with CAS performed for primary carotid artery
stenosis. In addition, we stratified redo cases in early and
late restenoses to establish any correlation between the time
of onset of restenosis and the periprocedural embolic load.
MATERIALS AND METHODS
Written informed consent was obtained from all pa-
tients in accordance with institutional guidelines.
Patients. Between December 1997 and June 2006,
the 812 patients scheduled for CAS in our tertiary referral
center for vascular disease were prospectively entered in a
computerized database and included in this study. Median
age was 71 years (interquartile range [IQR], 66-76 years),
and 569 (70%) were men.
In a subgroup of 72 patients (group 1), CAS was
performed for recurrent stenosis at a mean of 71 (SD 57)
months (range, 5-245 months) after previous ipsilateral
CEA. The median age in this subgroup was 70 years (IQR,
65-75 years) and 44 (61%) were men. In the 4 months
preceding CAS, 14 (19%) had demonstrated symptoms of
ipsilateral carotid artery stenosis, documented as transient
ischemic attack (TIA), transient monocular blindness
(TMB), or minor stroke. In four (29%), the symptoms
occurred36months after the initial ipsilateral CEA.Most
of the CEAs were performed in our institution.
The CAS procedures in the remaining 740 patients
(group 2) were performed for primary carotid bifurcation
stenosis. In this group, 525 (71%) were men, the median
age was 71 years (IQR, 66-76 years), and 147 (20%) had
recently been symptomatic. Baseline patient characteristics
are summarized in Table I.
In 588 patients (72%), CAS was performed before
coronary artery bypass grafting, cardiac valve replacement,
or reconstructive surgery of the thoracic aorta. These pa-
tients were treated to prevent perioperative complica-
tions,20 and 505 (86%) had not presented with symptoms
of ipsilateral carotid bifurcation stenosis.
Symptomatic patients were treated if the degree of
stenosis at the carotid bifurcation was 70% according to
Table I. Patient characteristics
Characteristic Group 1
Patients, No. 72
Male gender, No. (%) 44 (61)
Age median (IQR), y 70 (65-75)
Recent ipsilateral symptoms, No. (%)b 14 (19)
Side of stenting
Left 38
Right 34
CPD use, No. (%) 17 (24)
CPD, Cerebral protection device; IQR, interquartile range.
aComparing group 1 vs group 2; P  .05 was statistically significant.
bTransient ischemic attack, transient monocular blindness or minor stroke theNorth American Symptomatic Carotid EndarterectomyTrial (NASCET) criteria.2 For asymptomatic patients, the
cutoff for treatment was a diameter reduction of 80%. The
degree of stenosis was assessed by duplex ultrasound scan-
ning and intra-arterial digital subtraction angiography be-
fore endovascular treatment.
CAS procedure. In all patients, CAS was performed
using a standard protocol described in detail previously.7,19
All procedures were performed under local anesthesia from
a groin approach. Several different types of appropriately
sized self-expandable stents were used (Table II). Because
we started performing CAS in our institution before cere-
bral protection devices (CPDs) had been developed, 426
patients (52%), mainly in the early part of our experience,
were treated without these devices. The CPDs used are
listed in Table III. To prevent hypotension and bradycardia
resulting from carotid body compression, 0.5 mg of atro-
pine sulphate was administered in the primary stenting
cases. Because the ipsilateral carotid body generally is dys-
functional after prior CEA, atropine was not routinely
administered in post-CEA restenosis cases. All procedures
were performed by an experienced interventional cardiolo-
gist or an experienced interventional radiologist.
TCD monitoring. The technique of TCD monitor-
ing during CAS has been described in detail in previous
publications.7 During the various stages of the procedure,
isolated microembolic signals were recorded according to
Group 2 Total Pa
740 812
525 (71) 569 (70) .08
71 (66-76) 71 (66-76) .28
147 (20) 161 (20) .99
.60
391 429
349 383
369 (50) 386 (48) .0001
nths before procedure.
Table II. Types and numbers of stents used
Stent type Manufacturer No. (%)
Carotid Wallstent Boston Scientific, Natick, Mass 355 (54.1)
Acculink Guidant, Indianapolis, Ind 210 (25.9)
Precise Cordis J&J, Miami Lakes, Fla 103 (12.7)
Easy Wallstent Boston Scientific, Natick, Mass 84 (10.3)
Nex Boston Scientific, Natick, Mass 15 (1.8)
Carotid SE Medtronic, Minneapolis, Minn 13 (1.6)
Peripheral Wallstent Boston Scientific, Natick, Mass 4 (0.5)
Protegé EV3, Plymouth, Minn 3 (0.4)
Sinus Carotid Optimed, Ettlingen, Germany 2 (0.2)
Bridge Medtronic, Minneapolis, Minn 1 (0.1)
Not stented 22 (2.7)
Total 812 (100)the criteria described by the consensus committee.21 If the
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counted separately, heartbeats with microemboli were
counted as microembolic showers. Microembolic signals
were stratified to five procedural stages: (1) wiring/passing
of the stenosis, (2) predilation, (3) stent deployment, (4)
postdilation, and (5), if applicable, placement and retrieval
of a CPD.
Clinical outcome. All patients were formally assessed
before and after the procedure by a neurologist who was
not involved in the intervention. During CAS, a different
neurologist was present in the angiography suite. New
cerebral deficits persisting for 24 hours were regarded as
stroke, which was graded according to the modified Rankin
scale.22 Major strokes exceeded 3 on the Rankin scale,
whereas minor strokes did not. In patients with adverse
cerebral outcome, computed tomography (CT) or mag-
netic resonance imaging (MRI), or both, of the brain were
performed.
End points in the analyses were minor and major
strokes (ischemic and hemorrhagic), death, TIA, and TMB
during the procedure or 7 days after. Surrogate end
points were the number of TCD-detected cerebral micro-
emboli during the various stages of the procedure.
Statistics. TCD data are presented with mean and SD
and analyzed with the Mann-WhitneyU test. For binomial
data, the 2 test was used. To test interdependence of
variables, the Mantel-Haenszel test was used for binomial
data and univariate analysis for numeric variables. In all
cases, P  .05 was regarded as statistically significant.
RESULTS
Clinical results. A filtering type distal CPD was used
in 17 patients (24%) in group 1; CPDs were used in 369
(50%) in group 2, a difference that was statistically signifi-
cant (P  .001).
No stent was placed in 22 of 812 arteries (2.7%) in the
entire cohort. Two (2.8%) of these occurred in group 1,
and neither procedure led to complications. In group 2, 20
procedures (2.7%) were terminated without placement of a
Table III. Types and numbers of protection devices used
Type Manufacturer No. (%)
Epifilter EZ Boston Scientific, Natick, Mass 181 (22.3)
Epifilter Boston Scientific, Natick, Mass 98 (12.1)
Spider filter eV3, Plymouth, MN 28 (3.4)
Angioguard XP Cordis J&J, Miami Lakes, Fla 18 (2.2)
Angioguard Cordis J&J, Miami Lakes, Fla 14 (1.7)
Accunet RX Guidant, Indianapolis, Ind 12 (1.5)
Trap filter eV3, Plymouth, Minn 4 (0.5)
Emboshield Abbott, Santa Rosa, Calif 4 (0.5)
Percusurge Medtronic, Minneapolis, Minn 3 (0.4)
Neuroshield Abbott, Santa Rosa, Calif 1 (0.1)
Interceptor Medtronic, Minneapolis, Minn 1 (0.1)
Failed protection 5 (0.6)
No protection 421 (51.8)
Not stented 22 (2.7)
Total 812stent. In two of these patients, a major stroke occurredduring the initial angiography and the procedure was ter-
minated; therefore, overall procedural success was achieved
in 790 of 812 arteries (97.3%).
Clinical outcome is reported in Table IV. In 812 CAS
procedures, seven patients (0.9%) died. A major stroke
occurred in 10 additional patients (1.2%), including the
two discontinued procedures, and a further 21 (2.6%)
sustained a minor stroke. All strokes were confirmed by CT
or MRI imaging. The combined stroke and death rate in
the entire cohort was 38 of 812 (4.7%).
All fatalities and all strokes occurred in the primary CAS
treatment group, giving a combined stroke and death rate
in this group of 38 of 740 (5.1%). No strokes and no deaths
occurred among the 72 patients who underwent CEA after
CAS (P  .049). The Mantel-Haenszel test established
that this difference was independent of CPD use.
Five TIAs occurred in group 1 versus 46 in group 2 (P
.8). TMB occurred in one patient in group 1 versus nine in
group 2 (P .9).
TCD data. In 678 of 812 cases (83%), an adequate
temporal window was available for TCDmonitoring, com-
prising 65 of 72 (90%) in group 1 and 613 of 740 (83%) in
group 2. Fewer isolated microemboli were documented in
group 1 compared with group 2 in all phases of the proce-
dure except the phase of CPD use (Table V). This differ-
ence was influenced, however, by the use of CPDs, which
was much more prevalent in group 2. The influence of
CPDs on the microembolic load is presented in Table VI.
After correction for this difference using linear regression
analysis, the difference was no longer statistically signifi-
cant. The TCD data with correction for CPD use are
summarized in Tables VII and VIII, both for isolated
emboli and for embolic showers, respectively.
Subgroup analyses. To establish any correlation be-
tween the rapidity of restenosis formation and the cerebral
embolic load during CAS, an additional analysis was per-
formed within group 1. Patients treated with CAS 36
months after CEA were compared with those treated 60
months after CEA. After the initial CEA procedure, 21
patients were treated 36 months and 35 after 60
months. TCD data of this comparison are presented in
Table IV. Permanent cerebral deficits during CAS or 
1 week
Event Group 1a Group 2b P
Patients 72 740
Transient ischemic attack 5 46 .81
Transient monocular blindness 1 9 .90
Minor stroke 0 20 .15
Major stroke 0 10 .28
Death 0 8 .38
Any stroke or death 0 38 .049c
aCarotid angioplasty and stenting for restenosis after carotid endarterec-
tomy.
bCarotid angioplasty and stenting for primary carotid stenosis.
cStatistically significant.Tables IX and X. There was no statistically significant
y.
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tween early and late restenoses in any of the phases.
DISCUSSION
In this study, we analyzed the results of CAS for treat-
ment of restenosis after prior ipsilateral CEA compared
with that of primary carotid stenosis. No strokes or deaths
occurred in the post-CEA group compared with 38 strokes
or deaths in the much larger group of primary CAS patients
(P  .049). At first analysis, the TCD-detected cerebral
microembolic load was significantly lower in post-CEA
restenoses compared with primary cases. Multivariate re-
gression analysis, however, showed that this difference was
caused by a higher rate of CPD use in primary cases
compared with restenosis cases. CPDs designed to protect
the brain from clinically significant macroemboli have pre-
Table V. Number of isolated emboli and embolic shower
Stage
Group 1,a mean (SD)
With CPD Without C
Isolated
emboli
Embolic
showers
Isolated
emboli
Wiring 43.4 (24.0) 3.0 (4.6) 35.0 (33.8)
No. 16 16 47
Predilation 17.4 (14.8) 4.1 (6.3) 13.6 (20.5)
No. 12 12 28
Stent placement 78.4 (36.3) 30.8 (28.4) 51.8 (26.7) 1
No. 16 16 47
Postdilation 25.4 (14.3) 10.4 (27.3) 18.6 (17.1)
No. 16 16 45
CPD use 44.2 (31.2) 5.8 (7.1) NA
No. 16 16
Total 203.9 (68.8) 51.8 (55.3) 111.3 (51.8) 2
No. 16 16 47
CPD, Cerebral protection device; NA, not applicable; SD, standard deviatio
aCarotid angioplasty and stenting for restenosis after carotid endarterectom
bCarotid angioplasty and stenting for primary carotid stenosis.
Table VI. Mean (standard deviation) number of isolated
the procedure, comparing patients treated with and withou
Event
Isolated emboli, mean (SD)
CPD No CPD
Wiring 53.2 (45.1) 44.3 (51.7)
No. 295 357
Predilation 24.7 (20.2) 18.2 (22.5)
No. 262 300
Stent placement 77.5 (34.8) 53.5 (37.3)
No. 295 357
Postdilation 33.6 (42.5) 20.7 (21.8)
No. 295 338
CPD use 38.3 (36.6) NA
No. 295
Total 222.5 (113.8) 132.3 (89.1)
No. 295 357
CPD, Cerebral protection device; NA, not applicable.
aStatistical significance set at P  .05.viously, paradoxically, been shown to be associated with anincrease in TCD-detected cerebral microembolic load dur-
ing CAS.23,24
The low event rate establishes that CAS is a safe proce-
dure for restenosis after prior CEA. In a subgroup analysis,
we tried to determine whether the embolic load is affected
by the rapidity of restenosis occurrence. No statistically
significant differences were found between patients treated
for early versus late restenosis.
Endarterectomy for restenosis after prior CEA is gen-
erally considered to be more challenging than primary
CEA.11 In 1989 the American Heart Association (AHA)
issued guidelines for CEA.25 These guidelines allow a3%
perioperative risk of complications during CEA for asymp-
tomatic stenosis, 5% for patients with recent ipsilateral
TIAs,7% for recent ipsilateral stroke, and10% peripro-
cedural risk of complications for patients with recurrent
ing the various stages of the procedure
Group 2,b mean (SD)
With CPD Without CPD
olic
ers
Isolated
emboli
Embolic
showers
Isolated
emboli
Embolic
showers
.5) 53.6 (46.1) 2.3 (6.7) 45.7 (53.8) 2.0 (6.0)
280 280 310 310
.5) 25.0 (20.5) 4.2 (6.4) 18.7 (22.7) 2.5 (5.1)
251 251 2721 272
9.1) 77.3 (34.8) 39.4 (25.6) 53.8 (38.7) 15.9 (18.7)
280 280 310 310
.6) 33.9 (43.6) 6.8 (9.5) 21.0 (22.5) 3.4 (6.0)
280 280 293 293
37.9 (36.9) 6.3 (9.0) NA NA
280 280
4.5) 216.1 (95.1) 58.8 (36.6) 135.5 (93.2) 23.2 (23.0)
280 280 310 310
emboli and embolic showers during various phases of
ering
Microembolic showers
Pa CPD No CPD Pa
.0001 2.4 (6.6) 1.9 (5.8) .01
295 357
.0001 4.2 (6.4) 2.4 (5.0) .0001
262 300
.0001 38.9 (25.8) 16.2 (18.7) .0001
295 357
.0001 7.0 (11.2) 3.4 (6.4) .0001
295 338
6.3 (8.9) NA
295
.0001 58.4 (37.7) 23.3 (23.1) .0001
295 357s dur
PD
Emb
show
1.4 (4
47
1.2 (2
28
8.4 (1
47
3.5 (8
45
NA
4.4 (2
47
n.micro
t filt




stenosis after CEA. In several revisions of these guidelines,
JOURNAL OF VASCULAR SURGERY
Volume 50, Number 4 Vos et al 759we have not been able to find a revocation of the last figure,
and we therefore assume that the maximum of 10% com-
plications during CEA for restenosis is still prevalent ac-
cording to the AHA. In view of the results in this series as
well as previous research by other authors, a revision is
indicated. In our opinion, CAS in experienced hands
should be considered the primary treatment option for
restenosis after prior CEA.
Earlier series of CAS after CEA13-16,26 have also shown
a low periprocedural event rate comparable with our re-
sults. Only three previous studies27-29 have specifically
compared CAS for restenosis after CEA with CAS for
primary stenosis. None of them used TCD to establish the
periprocedural microembolic load, and neither did any
study find a significant difference in outcome between
Table VII. Mean (standard deviation) of isolated microem
Event
Gross number of microembol
Group 1b Group 2c
Wiring 37.0 (31.1) 50.5 (52.6)
No. 65 599
Predilation 14.8 (18.7) 21.7 (21.8)
No. 40 523
Stent placement 58.6 (31.1) 64.7 (38.8)
No. 64 592
Postdilation 20.4 (16.5) 27.2 (34.9)
No. 61 575
CPD 44.2 (30.2) 37.5 (36.9)
No. 16 282
Total 134.8 (68.7) 175.4 (113.8)
No. 65 599
CPD, Cerebral protection device.
aCorrection by multivariate regression analysis.
bCarotid angioplasty and stenting for restenosis after carotid endarterectom
cCarotid angioplasty and stenting for primary carotid stenosis.
dStatistically significant.
Table VIII. Mean (standard deviation) of microembolic s
Event
Gross number of embolic showe
Group 1b Group 2c
Wiring 1.7 (4.5) 2.2 (6.4)
No. 65 599
Predilation 2.0 (4.1) 3.3 (5.8)
No. 40 523
Stent placement 21.5 (22.0) 26.9 (25.2)
No. 64 593
Postdilation 5.3 (15.7) 5.0 (8.1)
No. 61 575
CPD 5.8 (6.9) 6.2 (9.0)
No. 16 282
Total 30.4 (36.0) 39.6 (35.1)
No. 65 599
CPD, Cerebral protection device.
aCorrection by multivariate regression analysis.
bCarotid angioplasty and stenting for restenosis after carotid endarterectom
cCarotid angioplasty and stenting for primary carotid stenosis.
dStatistically significant.groups for periprocedural stroke and death. Cuadra et al28concluded that CAS for restenosis should not be consid-
ered a low-risk procedure that is useful for training pur-
poses. Although we did find a difference that was favorable
for restenotic lesions, we agree that CAS should never be
considered to be an easy procedure, but should always be
performed by a highly experienced team. To our knowl-
edge, our study is the first to compare TCD results in
restenotic vs primary lesions. No difference in microem-
bolic load was established, which underscores the fact that
a significant embolic burden to the brain is present even in
restenotic lesions.
Many authors have postulated an association between
the time of onset of restenosis formation and the likelihood
of cerebral sequelae, suggesting that early restenoses are
less emboligenic than late restenoses17,30,31; however, only
stratified to procedural stage
Correction for CPD usea
P Group 1b Group 2c P
.017d 39.3 (6.2) 49.8 (2.0) .11
65 599
.001d 16.1 (3.4) 21.9 (0.9) .1
40 523
.119 64.3 (4.6) 65.8 (1.5) .77
64 592
.085 23.5 (4.3) 27.6 (1.4) .36
61 575
.218 43.4 (12.4) 37.2 (8.3) .51
16 282
.004d 156.6 (12.9) 180.3 (4.2) .08
65 599
ers stratified to procedural stage
Correction for CPD usea
P Group 1b Group 2c P
.66 3.7 (38.8) 14.5 (12.6) .66
65 599
.13 2.4 (0.9) 3.4 (0.248) .32
40 523
.25 26.9 (2.9) 27.8 (0.9) .77
63 593
.22 6.2 (1.2) 5.1 (0.4) .37
61 575
.82 9.2 (3.0) 9.6 (2.0) .87
16 282
.028d 39.7 (3.9) 41.3 (1.3) .71
65 599boli
i
y.how
rs
y.one author actually reported a difference.11
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ipsilateral CEA varies among reports from 2 years17,18,32,33 to
3 years.32,34,35 To avoid any possible overlap in the mecha-
nism of restenosis formation, we compared patients with an
interval between CEA and CAS of 3 years, presumably
MIH, with patients with an interval of 5 years, presumably
renewed atherosclerotic lesions. No statistically significant dif-
ference in cerebral embolic load was found. This appears to
imply that the risk of cerebral embolization during CAS for
post-CEA restenosis is independent from the time interval.
This study has several limitations. The first is the non-
randomized design. One consequence of the nonrandom-
ized design was that the primary stenting group contained
significantly more patients with a CPD than the redo
Table IX. Mean (standard deviation) number of isolated
microemboli in the various phases of the procedure in
patients after carotid endarterectomy
Event Early restenosesa Late restenosesb P
Wiring 29.5 (12.0) 47.0 (38.9) .13
No. 20 30
Predilation 11.6 (13.2) 19.6 (23.0) .36
No. 10 21
Stent placement 63.0 (30.8) 59.6 (25.2) .59
No. 20 30
Postdilation 26.2 (21.3) 17.5 (12.2) .31
No. 20 30
CPD use 40.0 (16.5) 43.8 (34.4) .65
No. 4 11
Total 125.0 (64.3) 152.6 (67.1) .26
No. 20 30
CPD, Cerebral protection device.
aInterval from carotid endarterectomy to carotid angioplasty and stenting
36 months.
bInterval carotid endarterectomy to carotid angioplasty and stenting 60
months.
Table X. Mean (standard deviation) number of showers
of microemboli in the various phases of the procedure in
patients after carotid endarterectomy
Event Early restenosesa Late restenosesb P
Wiring 0.7 (1.4) 3.2 (6.2) 0.28
No. 20 30
Predilation 2.0 (2.8) 2.6 (5.2) 0.88
No. 10 21
Stent placement 23.0 (23.1) 24.8 (23.5) 0.55
No. 20 30
Postdilation 5.1 (11.7) 6.6 (20.0) 0.73
No. 20 30
CPD use 4.8 (3.3) 6.6 (7.9) 0.9
No. 4 11
Total 29.1 (32.7) 39.0 (42.2) 0.22
No. 20 30
CPD, Cerebral protection device.
aInterval from carotid endarterectomy to carotid angioplasty and stenting
36 months.
bInterval carotid endarterectomy to carotid angioplasty and stenting 60
months.group. Univariate analysis and Mantel-Haenszel testingwere used to correct for this difference in baseline data, and
the difference in clinical outcome proved to be indepen-
dent from CPD use.
The second limitation was the relatively limited num-
ber of patients in the restenosis group and, particularly, in
the subgroups. We reported nonsignificant differences be-
tween the early and late restenosis groups and we acknowl-
edge that such may be due to the sample size. Increasing
the sample size lowers the probability of a type II error and
of the magnitude of the difference detectable.
Third, the use of TCD as a surrogate end point has a
number of limitations in monitoring cerebrovascular inter-
ventions, including that it cannot distinguish the size of
microemboli. CPDs have pores of up to 100 m to allow
passage of blood while capturing potentially significantly
larger particles. This may be one of the contributing factors
to the paradoxic increase in microembolic load in CPD
protected cases.
A further limitation was that clinical outcome is pre-
sented for the first week only compared with most other
studies that report all cerebral events 30 days as the
periprocedural event rate. In many patients in our series,
the CAS was performed in the workup before major cardio-
thoracic surgery that was scheduled between 1 week and 1
month after the CAS procedure. The data of the second
procedure might then have influenced the periprocedural
data on the CAS procedure. Accordingly in this study,
cerebral complications are represented for the first week
only. Almost all cerebral sequelae after CAS occur during
the procedure or within the first few hours after, so we do
not believe this significantly influenced our results.
CONCLUSION
This study indicates that CAS for restenosis after CEA
can be performed safely, with a complication rate and
cerebral embolic load that is as least as good as primary
CAS. The time interval between CEA and the occurrence
of the restenosis does not appear to influence these results.
We propose that CAS in experienced hands is an appropri-
ate treatment for post CEA restenosis.
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